Wednesday, August 23, 2023
Sanyou Biopharmaceuticals and Sinorda Biomedicine have recently entered into a strategic cooperation agreement to drive their innovative bispecific antibody drug project.
Under this agreement, Sanyou's cutting-edge core technology platform for integrated research and development (R&D) and preclinical development of innovative biological drugs will be combined with Sinorda's extensive experience in preclinical and clinical oncology immunotherapy, along with their world-class "super-trillion innovative biologics discovery platform.
This collaboration aims to collaboratively advance the research and development of the product pipeline. The combined strengths and robust collaboration will create fresh opportunities and establish a pioneering cooperative model between enterprises focused on innovative drug research and development services.
Working together with Sanyou boosts ability to speed up the development of new drugs and turn creative ideas into real treatments more rapidly. This partnership enhances the options available for patients seeking treatment by advancing innovative drug products and make a meaningful contribution to improve human health.
